Vir Biotechnology (NASDAQ:VIR), a clinical-stage biopharmaceutical company based in San Francisco, has attracted renewed attention following developments in oncology and infectious disease programs.
The company focuses on antibody-based therapeutics and immunologic technologies. Its strategic partnership with Astellas and emerging clinical data for lead assets have prompted analysts to reassess the stock's potential.
In February 2026, Vir announced a partnership with Astellas that includes $335 million in upfront and near-term payments, providing substantial capital to support ongoing development.
VIR-5500, the lead oncology candidate, targets prostate-specific membrane antigen using T-cell engager technology. Clinical data demonstrated strong prostate-specific antigen response rates and a favorable safety profile.
The combination therapy (elebsiran + tobevibart) for Hepatitis Delta showed deep antiviral activity in the SOLSTICE Phase 2 trial. Topline data from ECLIPSE trials is expected in the first quarter of 2027.
The Astellas partnership provides Vir with substantial financial resources and access to commercial infrastructure. The company now has a market capitalization of $1.53 billion.
